Trials / Completed
CompletedNCT06841445
Efficacy and Safety of HRS9531 Tablet in Obese Subjects
A Multicenter, Randomized, Double-blind, Placebo- Parallel Controlled, Phase II Study to Evaluate the Efficacy and Safety of HRS9531 Tablet in Obese Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 166 (actual)
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy of HRS9531 tablet compared with placebo in reducing body weight in obese subjects after 26 weeks of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS9531 Tablet | HRS9531 Tablet dose 1 |
| DRUG | HRS9531 Tablet | HRS9531 Tablet dose 2 |
| DRUG | HRS9531 Tablet | HRS9531 Tablet dose 3 |
| DRUG | HRS9531 Tablet placebo | HRS9531 Tablet placebo |
Timeline
- Start date
- 2025-04-07
- Primary completion
- 2026-01-08
- Completion
- 2026-01-08
- First posted
- 2025-02-24
- Last updated
- 2026-04-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06841445. Inclusion in this directory is not an endorsement.